



April 28, 2016

|                     |          |               |                   |
|---------------------|----------|---------------|-------------------|
| Company name        | 3 - D    | M a t r i x , | L t d .           |
| A d d r e s s       | 3-2-4    | Kojimachi,    | Chiyoda-ku, Tokyo |
| P r e s i d e n t   |          |               | Jun Okada         |
| C o d e N u m b e r |          |               | 7777              |
| C o n t a c t       | Director |               | Tomoyuki Arai     |
| T E L               |          |               | +81 3 (3511)3440  |

**Partnership Agreement concluded with Kaplan regarding sales and marketing of absorbable local hemostat “PuraStat®” in Chile**

Our consolidated subsidiary in Europe, 3-D Matrix Europe SAS. (“3DMEU”), and M. KAPLAN Y CIA LTDA, (“Kaplan”, head office located at Marchant Pereira 174, Providencia, Santiago, Chile D.F.) have entered into a partnership agreement for sales and marketing of our absorbable local hemostat “PuraStat®” in Chile on April 28<sup>th</sup>, 2016.

In this agreement, 3DMEU will grant sales and marketing license to Kaplan in Chile. The commercial sale of PuraStat® will take place from the beginning of this fiscal year.

In Chile, the medical expenditure capita is the second highest in South America and 97% of Chilean population of over 17 million people are covered with medical insurance. Medical device import value is increasing by 17% per year, grew by 4.3 times from 2003 to 2012<sup>\*1</sup>. Considering Chile is the important and high growing market, 3-D Matrix group will continue to develop and strengthen sales platform in Chile with Kaplan.

This announcement does not influence the earning forecast of the company at this moment. However, we will make necessary announcements when it is deemed that there is any influence.

Reference:

\*1 Source : JETRO, 「Medical Device Market in Central and South America」 October, 2013